News Releases

Month Year

Email Alerts

Dec 6, 2024

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Dec 2, 2024

Insmed To Present at December 2024 Investor Conferences
Nov 7, 2024

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Nov 6, 2024

Insmed To Present at November 2024 Investor Conferences
Oct 31, 2024

Insmed Reports Third-Quarter 2024 Financial Results and Provides Business Update
Oct 24, 2024

Insmed Ranks No. 1 on Science's 2024 Top Biopharma Employers List
Oct 23, 2024

Insmed Unites Across Communities Around the World During Third Annual Global Day of Good
Oct 17, 2024

Insmed to Host Third-Quarter 2024 Financial Results Conference Call on Thursday, October 31, 2024
Oct 8, 2024

New Subgroup Analyses from Landmark Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis Demonstrate Consistency with Positive Overall Trial Population Results
Oct 4, 2024

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sep 6, 2024

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Aug 8, 2024

Insmed Reports Second-Quarter 2024 Financial Results and Provides Business Update
Aug 2, 2024

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jul 29, 2024

Insmed to Host Second-Quarter 2024 Financial Results Conference Call on Thursday, August 8, 2024
Jul 5, 2024

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jul 3, 2024

Additional Positive Data from Pivotal ASPEN Study of Brensocatib in Patients with Bronchiectasis to be Presented at the 7th World Bronchiectasis Conference
Jun 27, 2024

Insmed Announces Redemption of all $225 Million of Outstanding 1.75% Convertible Senior Notes Due 2025
Jun 7, 2024

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jun 5, 2024

Insmed To Present at the Goldman Sachs 45th Annual Global Healthcare Conference
May 30, 2024

Insmed to Host Commercial Webinar on June 4, 2024
May 30, 2024

Insmed Announces Pricing of $650 Million Public Offering of Common Stock
May 28, 2024

Insmed Announces Proposed $500 Million Public Offering of Common Stock
May 28, 2024

Insmed Announces Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis
May 27, 2024

Insmed to Host Investor Call to Discuss Topline Results from Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis
May 20, 2024

Insmed Presents Positive Patient-Reported Outcomes and Microbiologic Data from Phase 3 ARISE Study Of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with NTM Lung Disease Caused by MAC at American Thoracic Society 2024 International Conference Plenary Session
May 9, 2024

Insmed Reports First-Quarter 2024 Financial Results and Provides Business Update
May 7, 2024

Insmed To Present at the BofA Securities Health Care Conference 2024
May 3, 2024

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Apr 25, 2024

Insmed to Host First-Quarter 2024 Financial Results Conference Call on Thursday, May 9, 2024
Apr 5, 2024

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Mar 27, 2024

Insmed to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International Conference
Mar 5, 2024

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Feb 29, 2024

Insmed To Present at Three March Conferences
Feb 28, 2024

Actress Jane Seymour and Insmed Raise Awareness of "Unseenism" and Empower People to Speak Up When It Comes to Their Health
Feb 22, 2024

Insmed Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Business Update
Feb 8, 2024

Insmed to Host Fourth-Quarter and Full Year 2023 Financial Results Conference Call on Thursday, February 22, 2024
Feb 2, 2024

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jan 5, 2024

Insmed Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference
Jan 4, 2024

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jan 2, 2024

Insmed To Present at the 42nd Annual J.P. Morgan Healthcare Conference
Dec 5, 2023

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Nov 29, 2023

Insmed To Present at the Nasdaq 49th Investor Conference
Nov 8, 2023

Insmed To Present at Two November Conferences
Nov 3, 2023

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Nov 2, 2023

Insmed Holds Second Annual Global Day of Good to Benefit Communities Across the Globe
Oct 26, 2023

Insmed Ranks No. 1 on Science's 2023 Top Biopharma Employers List
Oct 26, 2023

Insmed Reports Third-Quarter 2023 Financial Results and Provides Business Update
Oct 24, 2023

Insmed and Google Cloud Collaborate to Transform the Lives of Patients by Harnessing the Power of AI
Oct 12, 2023

Insmed to Host Third-Quarter 2023 Financial Results Conference Call on Thursday, October 26, 2023
Oct 6, 2023

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sep 26, 2023

Insmed To Present at Chardan's 7th Annual Genetic Medicines Conference
Sep 8, 2023

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sep 6, 2023

Insmed To Present at the Morgan Stanley 21st Annual Global Healthcare Conference
Sep 5, 2023

INSMED ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 ARISE STUDY OF ARIKAYCE® (AMIKACIN LIPOSOME INHALATION SUSPENSION) IN PATIENTS WITH NTM LUNG DISEASE CAUSED BY MAC
Aug 4, 2023

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Aug 3, 2023

Insmed Reports Second-Quarter 2023 Financial Results and Provides Business Update
Jul 20, 2023

Insmed to Host Second-Quarter 2023 Financial Results Conference Call on Thursday, August 3, 2023
Jul 7, 2023

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jun 7, 2023

Insmed To Present at the Goldman Sachs 44th Annual Global Healthcare Conference
Jun 6, 2023

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 22, 2023

Insmed Presents Range of New Study Findings at American Thoracic Society 2023 International Conference
May 8, 2023

Insmed Unveils New Research Platforms and Capabilities at Investor and Analyst Event, "The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More"
May 5, 2023

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 4, 2023

Insmed Reports First Quarter 2023 Financial Results and Provides Business Update
Apr 24, 2023

Insmed to Host Investor and Analyst Event on May 8, 2023
Apr 20, 2023

Insmed to Host First Quarter 2023 Financial Results Conference Call on Thursday, May 4, 2023
Apr 6, 2023

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Mar 31, 2023

Insmed Completes Enrollment of Adult Patients in Phase 3 ASPEN Study of Brensocatib in Bronchiectasis
Mar 24, 2023

Insmed to Present New Clinical, Pre-Clinical, and Real-World Data in Serious and Rare Lung Diseases at the American Thoracic Society 2023 International Conference
Mar 3, 2023

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Mar 1, 2023

Insmed To Present at Two March Conferences
Feb 23, 2023

Insmed Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Feb 9, 2023

Insmed to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call on Thursday, February 23, 2023
Feb 7, 2023

Insmed To Present at the SVB Securities Global Biopharma Conference
Feb 3, 2023

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jan 20, 2023

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jan 6, 2023

Insmed Provides Business Updates and Near-Term Strategic Outlook at 41st Annual J.P. Morgan Healthcare Conference
Jan 3, 2023

Insmed To Present at the 41st Annual J.P. Morgan Healthcare Conference
Dec 6, 2022

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Nov 30, 2022

Insmed To Present at the Nasdaq 47th Investor Conference
Nov 4, 2022

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Nov 1, 2022

Insmed To Present at Three November Conferences
Oct 27, 2022

Insmed Ranks No. 1 on Science's 2022 Top Biopharma Employers List
Oct 27, 2022

Insmed Reports Third Quarter 2022 Financial Results and Provides Business Update
Oct 19, 2022

Insmed Announces Strategic Financings Totaling $775 Million
Oct 13, 2022

Insmed to Host Third Quarter 2022 Financial Results Conference Call on Thursday, October 27, 2022
Oct 7, 2022

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Oct 6, 2022

Insmed Holds Inaugural Global Day of Good - A Company-Wide Day of Service
Sep 7, 2022

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sep 6, 2022

Insmed To Present at Two September Conferences
Aug 5, 2022

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Aug 4, 2022

Insmed Reports Second Quarter 2022 Financial Results and Provides Business Update
Jul 21, 2022

Insmed to Host Second Quarter 2022 Financial Results Conference Call on Thursday, August 4, 2022
Jul 8, 2022

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jun 3, 2022

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 23, 2022

Insmed Names Drayton Wise Chief Commercial Officer
May 17, 2022

Insmed Presents New Data Across Three Pillars at American Thoracic Society 2022 International Conference
May 17, 2022

Insmed To Present at the H.C. Wainwright Annual Global Life Sciences Conference
May 6, 2022

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 5, 2022

Insmed Reports First Quarter 2022 Financial Results and Provides Business Update

Show per page

Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your
email alerts.

View the latest Insmed Investor Presentation

Download

Our Global Company

Current Clinical Trials

Discovery Dialogues at Insmed

Responsibility Report

Our Global Company

Current Clinical Trials

Discovery Dialogues at Insmed

Responsibility Report

Footer